BridgeBio Pharma Inc. (BBIO) is a biopharmaceutical company that focuses on the development and commercialization of novel medicines to treat genetic diseases and cancers. The company's drug development programs target specific genetic mutations and disorders that are often overlooked by larger pharmaceutical companies. BridgeBio Pharma's pipeline includes more than 20 drug candidates in various stages of development, with a focus on rare genetic diseases and genetically driven cancers. The company operates through a network of subsidiaries, each focused on a specific area of research and drug development. BridgeBio Pharma is headquartered in Palo Alto, California, and as of September 2021, had a market capitalization of approximately $11.3 billion.
BridgeBio Pharma Inc. (BBIO) is a biopharmaceutical company that focuses on the development and commercialization of novel medicines to treat genetic diseases and cancers. The company's drug development programs target specific genetic mutations and disorders that are often overlooked by larger pharmaceutical companies. BridgeBio Pharma's pipeline includes more than 20 drug candidates in various stages of development, with a focus on rare genetic diseases and genetically driven cancers. The company operates through a network of subsidiaries, each focused on a specific area of research and drug development. BridgeBio Pharma is headquartered in Palo Alto, California, and as of September 2021, had a market capitalization of approximately $11.3 billion.